-
BGI Genomics and Technopark Biogen Launch Astana Genetic Center to Boost Genetic Testing in Central Asia
•
Astana Genetic Center, a collaboration between China’s leading genomics company BGI Genomics Co., Ltd (SHE: 300676) and Kazakhstan’s Technopark Biogen, has officially commenced operations. The center, located within the Kazakhstan National Biotechnology Center, is well-equipped with state-of-the-art gene sequencing and genetic data analysis machinery, aiming to facilitate early disease diagnosis…
-
BGI Genomics’ Subsidiary Inks 3-Year Noninvasive Prenatal Test Agreement with Heilongjiang Province
•
BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced that its subsidiary, Heilongjiang BGI Longjiang Medical Laboratory Co., Ltd, has entered into a three-year cooperation agreement with the Health Commission of Heilongjiang Province. This agreement focuses on providing noninvasive prenatal genetic testing services for…
-
BGI Genomics Delays Market Filing for BRCA1/2 Detection Kit Due to Incomplete Data
•
BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced an unsuccessful market filing for its BRCA1/2 gene mutation detection kit, which utilizes the combined probe anchored polymerization sequencing method. The company cited the failure to complete the required complement and correction of information as…
-
BGI Genomics Receives NMPA Approval for Innovative Colorectal Cancer Detection Kit
•
BGI Genomics Co., Ltd. (SHE: 300676), a leading genomics firm based in China, has announced the approval of its medical device license from the National Medical Products Administration (NMPA) for a novel gene methylation detection kit. The kit employs fluorescence PCR technology to assess the combined methylation status of the…
